SEC Form SC 13G/A filed by Windtree Therapeutics Inc. (Amendment)

2/14/24 4:30:23 PM ET

$WINT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $WINT alert in real time by email

SC 13G/A 1 tm246286d3_sc13ga.htm SC 13G/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

WINDTREE THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK, $0.001 PAR VALUE PER SHARE

(Title of Class of Securities)

97382D204

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

	¨	Rule 13d-1(b)
	x	Rule 13d-1(c)
	¨	Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Page 1 of 13 Pages)

SCHEDULE 13G

CUSIP NO. 97382D204

Page 2 of 13

1	NAMES OF REPORTING PERSONS Lincoln Park Capital Fund, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Illinois

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

339,167

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

339,167

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 339,167
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.181%⁽¹⁾/4.962%⁽²⁾
12	TYPE OF REPORTING PERSON OO

(1) Represents the calculated percent share of beneficial ownership of Common Stock as of December 31, 2023.

(2) Represents the calculated percent share of beneficial ownership of Common Stock as of February 9, 2024.

SCHEDULE 13G

CUSIP NO. 97382D204

Page 3 of 13

1	NAMES OF REPORTING PERSONS Lincoln Park Capital, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Illinois

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

339,167

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

339,157

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 339,167
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.181%⁽¹⁾/4.962%⁽²⁾
12	TYPE OF REPORTING PERSON OO

(1) Represents the calculated percent share of beneficial ownership of Common Stock as of December 31, 2023.

(2) Represents the calculated percent share of beneficial ownership of Common Stock as of February 9, 2024.

SCHEDULE 13G

CUSIP NO. 97382D204

Page 4 of 13

1	NAMES OF REPORTING PERSONS Rockledge Capital Corporation
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Texas

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

339,167

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

339,167

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 339,167
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.181%⁽¹⁾/4.962%⁽²⁾
12	TYPE OF REPORTING PERSON CO

(1) Represents the calculated percent share of beneficial ownership of Common Stock as of December 31, 2023.

(2) Represents the calculated percent share of beneficial ownership of Common Stock as of February 9, 2024.

SCHEDULE 13G

CUSIP NO. 97382D204

Page 5 of 13

1	NAMES OF REPORTING PERSONS Joshua B. Scheinfeld
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

339,167

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

339,167

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 339,167
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.181%⁽¹⁾/4.962%⁽²⁾
12	TYPE OF REPORTING PERSON IN

(1) Represents the calculated percent share of beneficial ownership of Common Stock as of December 31, 2023.

(2) Represents the calculated percent share of beneficial ownership of Common Stock as of February 9, 2024.

SCHEDULE 13G

CUSIP NO. 97382D204

Page 6 of 13

1	NAMES OF REPORTING PERSONS Alex Noah Investors, Inc.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Illinois

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

339,167

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

339,167

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 339,167
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.181%⁽¹⁾/4.962%⁽²⁾
12	TYPE OF REPORTING PERSON CO

(1) Represents the calculated percent share of beneficial ownership of Common Stock as of December 31, 2023.

(2) Represents the calculated percent share of beneficial ownership of Common Stock as of February 9, 2024.

SCHEDULE 13G

CUSIP NO. 97382D204

Page 7 of 13

1	NAMES OF REPORTING PERSONS Jonathan I. Cope
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

339,167

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

339,167

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 339,167
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.181%⁽¹⁾/4.962%⁽²⁾
12	TYPE OF REPORTING PERSON IN

(1) Represents the calculated percent share of beneficial ownership of Common Stock as of December 31, 2023.

(2) Represents the calculated percent share of beneficial ownership of Common Stock as of February 9, 2024.

SCHEDULE 13G

CUSIP NO. 97382D204

Page 8 of 13

Item 1.

	(a)	Name of Issuer:

		Windtree Therapeutics, Inc., a Delaware corporation (“Issuer”)

	(b)	Address of Issuer’s Principal Executive Offices:

		2600 Kelly Road, Suite 100
		Warrington, Pennsylvania

Item 2.

	(a)	Name of Person Filing:

		Lincoln Park Capital Fund, LLC (“LPC Fund”)
		Lincoln Park Capital, LLC (“LPC”)
		Rockledge Capital Corporation (“RCC”)
		Joshua B. Scheinfeld (“Mr. Scheinfeld”)
		Alex Noah Investors, Inc. (“Alex Noah”)
		Jonathan I. Cope (“Mr. Cope” and, collectively with LPC Fund, LPC, RCC, Mr. Scheinfeld and Alex Noah, the “Reporting Persons”)

	(b)	Address of Principal Business Office, or if None, Residence:

		The address of the principal business office of each of the Reporting Persons is:
		440 North Wells, Suite 410
		Chicago, Illinois 60654

	(c)	Citizenship:

		LPC Fund is an Illinois limited liability company
		LPC is an Illinois limited liability company
		RCC is a Texas corporation
		Mr. Scheinfeld is a United States citizen
		Alex Noah is an Illinois corporation
		Mr. Cope is a United States citizen

SCHEDULE 13G

CUSIP NO. 97382D204

Page 9 of 13

	(d)	Title of Class of Securities:

		Common Stock, par value $0.001 per share (“Common Stock”)

	(e)	CUSIP Number:

		97382D204

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	¨	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
(b)	¨	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	¨	Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	¨	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	¨	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	¨	An employee benefit plan or endowment fund in accordance with §240. 13d-1(b)(1)(ii)(F);
(g)	¨	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)	¨	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	¨	A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)	¨	Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution ______________________

SCHEDULE 13G

CUSIP NO. 97382D204

Page 10 of 13

Item 4.

Ownership.

Reporting person	Amount beneficially owned¹:	Percent of class:	Sole power to vote or direct the vote:	Shared power to vote or to direct the vote:	Sole power to dispose or to direct the disposition of:	Shared power to dispose or to direct the disposition of:
Lincoln Park Capital Fund, LLC	339,167	6.181%⁽²⁾/4.962%⁽³⁾	0	339,167	0	339,167
Lincoln Park Capital, LLC	339,167	6.181%⁽²⁾/4.962%⁽³⁾	0	339,167	0	339,167
Rockledge Capital Corporation	339,167	6.181%⁽²⁾/4.962%⁽³⁾	0	339,167	0	339,167
Joshua B. Scheinfeld	339,167	6.181%⁽²⁾/4.962%⁽³⁾	0	339,167	0	339,167
Alex Noah Investors, Inc.	339,167	6.181%⁽²⁾/4.962%⁽³⁾	0	339,167	0	339,167
Jonathan I. Cope	339,167	6.181%⁽²⁾/4.962%⁽³⁾	0	339,167	0	339,167

1 Represents (i) a warrant to purchase 307,167 shares of Common Stock (the “April Warrant”) purchased by LPC Fund directly from the Issuer in a private placement (the “Private Placement”) and (ii) a warrant to purchase 32,000 shares of Common Stock (the “January Warrant,” and together with the April Warrant, the “Warrants”) purchased by LPC Fund directly from the Issuer in the Issuer’s offering of warrants on January 24, 2023.

2 As of December 31, 2023, LPC Fund beneficially owned, directly, (i) 32,000 shares currently exercisable under the January Warrant and (ii) 307,167 shares currently exercisable under the April Warrant. Based on the information contained in the Issuer’s Prospectus Supplement, filed with the Securities and Exchange Commission on November 9, 2023, there was a total of 5,148,219 shares of Common Stock outstanding as of November 7, 2023, which does not include the shares issuable upon exercise of the Warrants issued to LPC Fund. The percentage is calculated as of November 7, 2023, and assumes that all of the shares of Common Stock currently underlying the Warrants were issued and outstanding as of December 31, 2023.

3 As of February 9, 2024, LPC Fund beneficially owned, directly, (i) 32,000 shares currently exercisable under the January Warrant and (ii) 307,167 shares currently exercisable under the April Warrant. Based on the information contained in the Issuer’s Prospectus Supplement, filed with the Securities and Exchange Commission on January 16, 2024, there was a total of 6,496,602 shares of Common Stock outstanding as of January 16, 2024, which does not include the shares issuable upon exercise of the Warrants issued to LPC Fund. The percentage is calculated as of January 16, 2024, and assumes that all of the shares of Common Stock currently underlying the Warrants were issued and outstanding as of February 9, 2024. The updated disclosure as of February 9, 2024 is included solely to reflect the beneficial ownership by the Reporting Persons of less than 5% of the outstanding shares of Common Stock and cessation of further reporting thereby on Schedule 13G.

The January Warrant is currently exercisable at a price of $10.76 per share (subject to adjustment as provided in the January Warrant), subject to a 4.99% beneficial ownership cap that prohibits the issuance of shares of Common Stock upon exercise of the January Warrant to the extent such issuance would cause the holder’s beneficial ownership of Common Stock (as calculated pursuant to Section 13(d) of the Act and Rule 13d-3 promulgated thereunder) to exceed 4.99% of the outstanding Common Stock, and expires on January 24, 2028. The April Warrant will be issued and will become exercisable on April 24, 2023 at a price of $2.93 per share (subject to adjustment as provided in the April Warrant), subject to a 9.99% beneficial ownership cap that prohibits the issuance of shares of Common Stock upon exercise of the April Warrant to the extent such issuance would cause the holder’s beneficial ownership of Common Stock (as calculated pursuant to Section 13(d) of the Act and Rule 13d-3 promulgated thereunder) to exceed 9.99% of the outstanding Common Stock, and expires on April 24, 2028.

LPC is the Managing Member of LPC Fund. RCC and Alex Noah are the Managing Members of LPC. Mr. Scheinfeld is the president and sole shareholder of RCC, as well as a principal of LPC. Mr. Cope is the president and sole shareholder of Alex Noah, as well as a principal of LPC. As a result of the foregoing, Mr. Scheinfeld and Mr. Cope have shared voting and shared investment power over the shares of Common Stock of the Issuer held directly by LPC Fund.

SCHEDULE 13G

CUSIP NO. 97382D204

Page 11 of 13

Pursuant to Section 13(d) of the Act and the rules thereunder, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope may be deemed to be a beneficial owner of the shares of Common Stock of the Issuer beneficially owned directly by LPC Fund.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Pursuant to Rule 13d-4 of the Act, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope disclaims beneficial ownership of the shares of Common Stock of the Issuer held directly by LPC Fund.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SCHEDULE 13G

CUSIP NO. 97382D204

Page 12 of 13

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2024

LINCOLN PARK CAPITAL FUND, LLC			LINCOLN PARK CAPITAL, LLC

BY:	LINCOLN PARK CAPITAL, LLC		BY:	ROCKLEDGE CAPITAL CORPORATION

BY:	ROCKLEDGE CAPITAL CORPORATION


By:	/s/ Joshua B. Scheinfeld		By:	/s/ Joshua B. Scheinfeld
	Name:	Joshua B. Scheinfeld		Name:	Joshua B. Scheinfeld
	Title:	President		Title:	President

LINCOLN PARK CAPITAL FUND, LLC			LINCOLN PARK CAPITAL, LLC

BY:	LINCOLN PARK CAPITAL, LLC		BY:	ALEX NOAH INVESTORS, INC.

BY:	ALEX NOAH INVESTORS, INC.


By:	/s/ Jonathan I. Cope		By:	/s/ Jonathan I. Cope
	Name:	Jonathan I. Cope		Name:	Jonathan I. Cope
	Title:	President		Title:	President

ROCKLEDGE CAPITAL CORPORATION			ALEX NOAH INVESTORS, INC.


By:	/s/ Joshua B. Scheinfeld		By:	/s/ Jonathan I. Cope
	Name:	Joshua B. Scheinfeld		Name:	Jonathan I. Cope
	Title:	President		Title:	President

JOSHUA B. SCHEINFELD			JONATHAN I. COPE


By:	/s/ Joshua B. Scheinfeld		By:	/s/ Jonathan I. Cope
	Name:	Joshua B. Scheinfeld		Name:	Jonathan I. Cope
	Title:	President		Title:	President

SCHEDULE 13G

CUSIP NO. 97382D204

Page 13 of 13

LIST OF EXHIBITS

Exhibit No.	Description

99.1	Joint Filing Agreement

Get the next $WINT alert in real time by email

SEC Form SC 13G/A filed by Windtree Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$WINT

$WINT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Kelly Leanne

President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

SEC Form 3 filed by new insider Pelletier Saundra L

$WINT
SEC Filings

Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

SEC Form EFFECT filed by Windtree Therapeutics Inc.

$WINT
Financials

Live finance-specific insights

$WINT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

Fraser Craig bought $2,550 worth of shares (2,500 units at $1.02), increasing direct ownership by 5% to 57,877 units (SEC Form 4)

Fraser Craig bought $2,250 worth of shares (2,500 units at $0.90), increasing direct ownership by 5% to 55,377 units (SEC Form 4)

$WINT
Press Releases

Fastest customizable press release news feed in the world

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development

$WINT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

$WINT
Leadership Updates

Live Leadership Updates

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Windtree Announces Leadership Transition Plan With Industry Veterans

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

$WINT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

SEC Form SC 13G filed by Windtree Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

SEC Form SC 13G/A filed by Windtree Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $WINT

$WINT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Kelly Leanne

President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

SEC Form 3 filed by new insider Pelletier Saundra L

$WINT SEC Filings

Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

SEC Form EFFECT filed by Windtree Therapeutics Inc.

$WINT Financials

Live finance-specific insights

$WINT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

Fraser Craig bought $2,550 worth of shares (2,500 units at $1.02), increasing direct ownership by 5% to 57,877 units (SEC Form 4)

Fraser Craig bought $2,250 worth of shares (2,500 units at $0.90), increasing direct ownership by 5% to 55,377 units (SEC Form 4)

$WINT Press Releases

Fastest customizable press release news feed in the world

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development

$WINT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

$WINT Leadership Updates

Live Leadership Updates

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Windtree Announces Leadership Transition Plan With Industry Veterans

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

$WINT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

SEC Form SC 13G filed by Windtree Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

Recent Analyst Ratings for
$WINT

$WINT
Insider Trading

$WINT
SEC Filings

$WINT
Financials

$WINT
Insider Purchases

$WINT
Press Releases

$WINT
Analyst Ratings

$WINT
Leadership Updates

$WINT
Large Ownership Changes